Successful Laser Treatment of Vandetanib-Associated Cutaneous PigmentationBROOKS, Sara; LINEHAN, W. Marston; SRINIVASAN, Ramaprasad et al.Archives of dermatology (1960). 2011, Vol 147, Num 3, pp 364-365, issn 0003-987X, 2 p.Article

A New Spectrum of Skin Toxic Effects Associated With the Multikinase Inhibitor VandetanibGIACCHERO, Damien; RAMACCIOTTI, Constanza; ROBERT, Caroline et al.Archives of dermatology (1960). 2012, Vol 148, Num 12, pp 1418-1420, issn 0003-987X, 3 p.Article

Cutaneous Pigmentation After Photosensitivity Induced by Vandetanib TherapyKONG, Heidi H; FINE, Howard A; STERN, Jere B et al.Archives of dermatology (1960). 2009, Vol 145, Num 8, pp 923-925, issn 0003-987X, 3 p.Article

Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequencesAZZARITI, Amalia; PORCELLI, Letizia; PARADISO, Angelo et al.Cancer chemotherapy and pharmacology. 2010, Vol 65, Num 2, pp 335-346, issn 0344-5704, 12 p.Article

Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinomaKLEIN, Jonah D; CHRISTOPOULOS, Apostolos; AHN, Sun M et al.Head & neck. 2012, Vol 34, Num 9, pp 1269-1276, issn 1043-3074, 8 p.Article

Vandetanib for the Treatment of Thyroid CancerLANGMUIR, P. B; YVER, A.Clinical pharmacology and therapeutics. 2012, Vol 91, Num 1, pp 71-80, issn 0009-9236, 10 p.Article

Angiogenèse et cancer de la thyroïde : Antiangiogéniques (2e partie) = Angiogenesis and thyroid cancerCOLICHI, C; BILLARD, D; FAIVRE, S et al.La Lettre du cancérologue (Boulogne). 2010, Vol 19, Num 10, pp 596-599, issn 1165-113X, 4 p.Article

Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequencesAZZARITI, Amalia; PORCELLI, Letizia; PARADISO, Angelo et al.Cancer chemotherapy and pharmacology. 2010, Vol 65, Num 5, pp 335-346, issn 0344-5704, 12 p.Article

Pharmacokinetics of Vandetanib: Three Phase I Studies in Healthy SubjectsMARTIN, Paul; OLIVER, Stuart; KENNEDY, Sarah-Jane et al.Clinical therapeutics. 2012, Vol 34, Num 1, pp 221-237, issn 0149-2918, 17 p.Article

Pharmacokinetics and Tolerability of Vandetanib in Chinese Patients With Solid, Malignant Tumors: An Open-Label, Phase I, Rising Multiple-Dose StudyLI ZHANG; SU LI; YANG ZHANG et al.Clinical therapeutics. 2011, Vol 33, Num 3, pp 315-327, issn 0149-2918, 13 p.Article

The Role of Antiangiogenetic Agents in the Treatment of Breast CancerBARESCHINO, M. A; SCHETTINO, C; COLANTUONI, G et al.Current medicinal chemistry. 2011, Vol 18, Num 33, pp 5022-5032, issn 0929-8673, 11 p.Article

Impact of Tumor Cell VEGF Expression on the In Vivo Efficacy of Vandetanib (ZACTIMA™; ZD6474)SIEMANN, Dietmar W; NORRIS, Christina M; RYAN, Anderson et al.Anticancer research. 2009, Vol 29, Num 6, pp 1987-1992, issn 0250-7005, 6 p.Article

Vandetanib Improves Anti-Tumor Effects of L19mTNFα in Xenograft Models of Esophageal CancerCRESCENZI, Marika; PERSANO, Luca; ESPOSITO, Giovanni et al.Clinical cancer research (Print). 2011, Vol 17, Num 3, pp 447-458, issn 1078-0432, 12 p.Article

Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic ImpairmentWEIL, Angelika; MARTIN, Paul; SMITH, Robert et al.Clinical pharmacokinetics. 2010, Vol 49, Num 9, pp 607-618, issn 0312-5963, 12 p.Article

Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomicsMAYER, Erica L; ISAKOFF, Steven J; KLEMENT, Giannoula et al.Breast cancer research and treatment. 2012, Vol 136, Num 1, pp 169-178, issn 0167-6806, 10 p.Article

Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomasKUMMAR, Shivaani; GUTIERREZ, Martin E; TREPEL, Jane et al.European journal of cancer (1990). 2011, Vol 47, Num 7, pp 997-1005, issn 0959-8049, 9 p.Article

A Novel Therapeutic Combination for Neuroblastoma: The Vascular Endothelial Growth Factor Receptor/Epidermal Growth Factor Receptor/Rearranged During Transfection Inhibitor Vandetanib With 13-cis-Retinoic AcidZAGE, Peter E; LIZHI ZENG; PALLA, Shana et al.Cancer. 2010, Vol 116, Num 10, pp 2465-2475, issn 0008-543X, 11 p.Article

Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid CancerWELLS, Samuel A; GOSNELL, Jessica E; GAGEL, Robert F et al.Journal of clinical oncology. 2010, Vol 28, Num 5, pp 767-772, issn 0732-183X, 6 p.Article

Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancerHEYMACH, John V; JOHNSON, Bruce E; KENNEDY, Sarah J et al.Journal of clinical oncology. 2007, Vol 25, Num 27, pp 4270-4277, issn 0732-183X, 8 p.Article

Phase I Trial, Pharmacokinetics, and Pharmacodynamics of Vandetanib and Dasatinib in Children with Newly Diagnosed Diffuse Intrinsic Pontine GliomaBRONISCER, Alberto; BAKER, Sharyn D; BAKER, Justin N et al.Clinical cancer research (Print). 2013, Vol 19, Num 11, pp 3050-3058, issn 1078-0432, 9 p.Article

Toxic cardiomyopathy leading to fatal acute cardiac failure related to vandetanib: a case report with histopathological analysisSELBACH SCHEFFEL, Rafael; DORA, José Miguel; SIQUEIRA, Débora R et al.European journal of endocrinology. 2013, Vol 168, Num 6, issn 0804-4643, K51-K54Article

Vandetanib: In Medullary Thyroid CancerFRAMPTON, James E.Drugs (Basel). 2012, Vol 72, Num 10, pp 1423-1436, issn 0012-6667, 14 p.Article

vandétanib ^(CAPRELSA°) Trop dangereux dans les cancers médullaires de la thyroïdeLa Revue Prescrire. 2012, Vol 32, Num 342, pp 256-259, issn 0247-7750, 4 p.Article

Phase I Study of Vandetanib During and After Radiotherapy in Children With Diffuse Intrinsic Pontine GliomaBRONISCER, Alberto; BAKER, Justin N; KOCAK, Mehmet et al.Journal of clinical oncology. 2010, Vol 28, Num 31, pp 4762-4768, issn 0732-183X, 7 p.Article

Les progrès dans le traitement des cancers de la thyroïde à l'ère des thérapies ciblées moléculaires = Advances in the treatment of thyroid cancer in the era of molecularly targeted therapiesMALOUF, G; BAUDIN, E; SERIA, J.-C et al.Bulletin du cancer. 2009, Vol 96, Num 1, pp 95-101, issn 0007-4551, 7 p.Article